RT Journal Article SR Electronic T1 Significance of the Multi-gene Panel myRisk in Japan JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4097 OP 4102 DO 10.21873/anticanres.15907 VO 42 IS 8 A1 SAORI HAYASHI A1 MAKOTO KUBO A1 SAWAKO MATSUZAKI A1 MASAYA KAI A1 TAKAFUMI MORISAKI A1 MAI YAMADA A1 KAZUHISA KANESHIRO A1 YUKA TAKAO A1 AKIKO SHIMAZAKI A1 KINUKO NAGAYOSHI A1 YUSUKE MIZUUCHI A1 MASAFUMI NAKAMURA YR 2022 UL http://ar.iiarjournals.org/content/42/8/4097.abstract AB Background/Aim: Hereditary tumors are estimated to account for approximately 5-10% of all tumors. In Europe and the United States, multi-gene panel testing (MGPT) is the standard method used for identifying potential causative genes. However, MGPT it is still not widely used in Japan. The aim of this study was to assess the risk of hereditary tumors in Japanese cancer patients using germline MGPT and provide an overview of MGPT in the Japanese medical system. Patients and Methods: We used the myRiskTM, a 35-gene panel that determines the risk for eight hereditary cancers: breast, ovarian, gastric, colorectal, prostate, pancreatic, malignant melanoma, and endometrial cancers. Results: From June 2019 to March 2020, 21 patients who were suspected to have hereditary tumors were included, based on their family or medical history. Pathogenic variants were found in 7 patients [BRCA1 (5), MSH6 (1), TP 53 (1)]. Conclusion: In this study, despite the small number of participants, we were able to show the significance of MGPT in Japan. Therefore, MGPT should be used for evaluating hereditary tumors in clinical practice.